Physician profile
David J Packey
NPI 1316944788
$11,236.08
in general payments reported to CMS, 2019-2025
53 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,922 · 2020: $990 · 2021: $1,638 · 2022: $1,209 · 2023: $1,674 · 2024: $1,580 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,459 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,458.94 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,087.16 | 2019-2025 | |
| Abbvie INC. | $1,084.70 | 2021-2025 | |
| Ucb, INC. | $911.26 | 2019-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $775.52 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $623.09 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $536.88 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $521.26 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $521.24 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $434.08 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Genzyme Corporation | $433.55 | 2019-2023 | |
| Pfizer INC. | $373.06 | 2023-2024 | |
| Sk Life Science, INC. | $313.15 | 2020-2025 | |
| Amgen INC. | $309.34 | 2019-2022 | |
| Neurelis, INC. | $288.57 | 2021-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $260.18 | 2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Packey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.